Alnylam on Wednesday unveiled positive data from a late-stage clinical trial for a drug candidate known as givosiran, the company’s second rare disease treatment to rely on the Nobel Prize-winning gene-silencing technique known as RNA interference.

Givosiran takes aim at a family of rare diseases known as acute hepatic porphyrias, which can cause abdominal issues that can be fatal. The study, which included 94 people in 18 countries, found that people on the drug had fewer attacks related to the genetic disorder over the course of six months. Five other secondary measurements also showed significant improvements.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy